News

Looking back on specialty equipment distributors stocks’ Q1 earnings, we examine this quarter’s best and worst performers, ...
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...
Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing ...
The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...
Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.
Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a ...
Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...
Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...
Eli Lilly and Company has agreed to acquire SiteOne Therapeutics Inc., a private biotech company developing small molecule ...